Redesigning Reach: Community-Based Research In Action – Part 3

As our series on community‑based research continues, one thing is clear: the industry is aligned on the promise - but still working through execution.

In partnership with Citeline, we surveyed 130 leaders from biotech companies, pharmaceutical organizations and CROs to understand how community‑centric models are being evaluated in practice. In previous articles, we explored key survey findings and perceived barriers in community-based research. When asked about the perceived benefits of community‑based research, respondents pointed to consistent areas of value:

• 69% cite improved patient retention
• 68% cite improved data quality
• 63% cite greater participant diversity
• 63% cite shorter trial timelines

Confidence in the model is similarly strong: Nearly 90% of respondents believe data quality is equivalent to or better than traditional site‑based trials

At the same time, the rate of adoption tells a more nuanced story:

• 56% of organizations have begun integrating community‑based approaches into their trial strategies
• But only 25% report full implementation at scale

Together, these findings highlight a clear inflection point. Community‑based research is widely viewed as beneficial - but translating that perceived value into consistent, scalable execution remains the next challenge for the industry. In this article, we outline how research organizations can fully embrace community‑based research and translate principle into practice across future studies.

Putting idea into practice

As with any research model, adoption depends largely on three fundamentals:

• Credible return on investment
• Strong operational backing
• Clear, visible proof points

Before committing further resources, stakeholders want evidence that community-based approaches can drive efficiency across recruitment, data collection, and site engagement.

Engaging experienced partners is a critical first step. Community‑based research upholds the same clinical rigor and protocol discipline as traditional trials, and experienced teams are essential to executing that rigor consistently across diverse settings. Their expertise helps manage operational complexity while maintaining data quality and compliance from start to finish.

Investment in infrastructure is equally critical. Beyond digital tools and remote monitoring, organizations need the operational framework to support community‑based research consistently. Standardized approaches to protocol adherence, data verification, and regulatory documentation must extend across all settings, from mobile visits to community‑based and hybrid trial models.

Finally, real‑world data is essential. Stakeholders want clear evidence that community‑based models deliver measurable value alongside operational feasibility. That includes demonstrated improvements in timelines and patient engagement, without sacrificing protocol compliance. As that evidence base grows, community‑based models move from a perceived risk to a proven driver of performance.

Measuring success

Traditional performance metrics such as enrollment speed, protocol adherence, and site productivity remain essential. However, on their own, they do not fully reflect the real‑world dynamics increasingly shaping trial design. Factors like access to care, shifting demographic patterns in disease burden, and growing regulatory focus on inclusion are becoming central to how new treatments are developed and evaluated. Community‑based models bridge this gap by pairing established performance metrics with real‑world context, offering a more complete view of study success.

When supported by the right infrastructure, community-based models offer a clear pathway to:

• Reach populations historically excluded from research
• Generate more inclusive study data
• Reduce patient burden without compromising oversight or quality

Beyond access and efficiency, community‑based approaches also create meaningful differentiation. In competitive therapeutic areas, demonstrating innovation in trial execution alongside innovation in molecule development can influence how regulators, sponsors, and patients engage with research. In this context, the trial model itself becomes part of the overall product narrative.

Because the potential cost associated with study delays, operational failures, and unmet endpoints is high, sustained adoption depends on clear, outcome‑based evidence. Sponsors and investors need data that demonstrates performance in real conditions, including validated case studies, credible ROI modeling, and longitudinal outcomes tied to patient adherence, real‑world effectiveness, and regulatory acceptance. Community‑based trials supported by this level of evidence will continue to build confidence and drive long‑term investment across the industry.

Moving forward

As the industry works through questions of execution and infrastructure, community‑based research is moving into clearer focus as a viable, repeatable trial model. When applied intentionally, it provides a rigorous approach to addressing complex studies and geographically dispersed patient populations.

There are clear signs that this shift is already underway. Trial design decisions are increasingly shaped by considerations of equity, efficiency, and collaboration across the research ecosystem. As a result, community‑based approaches are being treated less as proofs of concept and more as practical tools for delivering trials that reflect the complexity of real‑world care. In fact, 72% of survey respondents expect community‑based models to play a larger role in their organization’s trials over the next five years, reinforcing the direction the industry is heading.

At EmVenio, our community‑based model is designed to expand patient access while maintaining the rigor required for high‑quality clinical research. Through scalable systems, aligned teams, and strong partnerships, we support trial execution without compromising oversight or data integrity. Contact us to learn more about how we can support your next study.